Mary Jane Rorick, PA
Physician Assistant · Oklahoma City, OKNPI 1407016306
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 640 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $5,219 and has fallen 86.4% since, to $712 in 2025. Among physician assistant clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 640 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$2K
- UCB, Inc.$2K
- AbbVie$1K
- Johnson & Johnson$1K
- GSK$831
- plus $5K from 22 others
What the payments were for
- Travel & lodging$40%
- Food & beverage$14,04099%
- Education$1751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 108 | $2,405 |
| AstraZeneca(2 entities) | 76 | $1,896 |
| UCB, Inc. | 93 | $1,641 |
| AbbVie | 65 | $1,466 |
| Johnson & Johnson | 53 | $1,145 |
| GSK | 34 | $831 |
| Lilly USA, LLC | 28 | $708 |
| Janssen Scientific Affairs, LLC | 5 | $527 |
| Novartis | 27 | $476 |
| Organon | 25 | $443 |
| Boehringer Ingelheim | 19 | $416 |
| Aurinia Pharma U.S., Inc. | 15 | $364 |
| Mallinckrodt Hospital Products Inc. | 12 | $320 |
| ANI Pharmaceuticals, Inc. | 22 | $291 |
| Pfizer | 14 | $270 |
| Genentech USA, Inc. | 10 | $169 |
| Actelion Pharmaceuticals US, Inc. | 6 | $167 |
| Kyowa Kirin, Inc. | 2 | $152 |
| Fresenius Kabi USA, LLC | 6 | $146 |
| Radius Health, Inc. | 5 | $107 |
| E.r. Squibb & Sons, L.L.C. | 5 | $101 |
| Sandoz | 3 | $56 |
| Scilex Pharmaceuticals Inc. | 2 | $32 |
| Sanofi | 1 | $24 |
| Nalu Medical, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,219 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 84 | $893,886 |
| Enbrel SureclickEtanercept | 45 | $330,915 |
| RinvoqUpadacitinib | 21 | $139,601 |
| Xeljanz XrTofacitinib Citrate | 15 | $84,905 |
| Cimzia (2 Pack)Certolizumab Pegol | 14 | $78,250 |
| Actemra ActpenTocilizumab | 16 | $77,172 |
| OlumiantBaricitinib | 13 | $71,047 |
| BenlystaBelimumab | 12 | $58,110 |
| Hydroxychloroquine Sulfate | 333 | $18,567 |
| Leflunomide | 220 | $18,404 |
| MethotrexateMethotrexate Sodium | 121 | $2,259 |
| Azathioprine | 36 | $1,903 |
| Sulfasalazine | 44 | $1,676 |
| Duloxetine Hcl | 34 | $1,304 |
| Colchicine | 16 | $1,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,466 | $139,60121 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,641 | $78,25014 claims |
| Lilly USA, LLCOlumiant | $708 | $71,04713 claims |
| GSKBenlysta | $831 | $58,11012 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $32 | $1,24416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Oklahoma City
- Jennifer SmithOklahoma City$134K
- Sarah HawkOklahoma City$23K
- Brooke CromerOklahoma City$14K
- Alma HintzeOklahoma City$14K
- Emily McLainOklahoma City$13K
- Deniz AktasOklahoma City$13K
- Jovonne SmithOklahoma City$12K
- Anthony SharpOklahoma City$11K
- Whitney PriceOklahoma City$11K
- Karon PotterOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.